Atovaquone

Atovaquone is a naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position. Among its listed roles, it functions as a antimalarial, an antifungal agent, an EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor, an EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor and an EC 1.10.2.2 (quinol–cytochrome-c reductase) inhibitor. It belongs to the class of monochlorobenzenes and a hydroxy-1,4-naphthoquinone. Atovaquone is an antiprotozoal prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the prevention and treatment of Pneumocystis pneumonia (PCP) in adults and adolescents who cannot tolerate sulfamethoxazole/trimethoprim. PCP can be an opportunistic infection (OI) of HIV. Its therapeutic use is listed as anti-infectives, antimalarials, antiparasitics and antiprotozoals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Acuvel, Mepron (antipneumocystic) and Wellvone. Its PubChem CID is 74989.